Prognostic factors in advanced multiple myeloma patients treated with the association of bortezomib, melphalan, prednisone and thalidomide (VMPT)

被引：0
|
作者：
Palumbo, A. [1 ]
Gay, F. [1 ]
Ambrosini, M. T. [1 ]
Benevolo, G. [2 ]
Pregno, F. [2 ]
Pescosta, N.
Callea, V [3 ]
Cangialosi, C. [4 ]
Caravita, T. [5 ]
Morabito, F. [6 ]
Musto, P. [7 ]
Larocca, A. [1 ]
Caltagirone, S. [1 ]
Avonto, I [1 ]
Cavallo, F. [1 ]
Boccadoro, M. [1 ]
机构：
[1] Univ Turin, Az Osp S Giovanni Battista, Div Ematol, Turin, Italy
[2] Azienda Osped San Giovanni Battista, Turin, Italy
[3] Osped Riuniti Bergamo, Div Ematol, Reggio Di Calabria, Italy
[4] Azienda Osped Cervello, Div Ematol Trapianto Midollo Osseo, Palermo, Italy
[5] Univ Roma Tor Vergata, Osped San Eugenio, Cattedra & Div Ematol, Rome, Italy
[6] Azienda Osped Cosenza, UOC Ematol, Cosenza, Italy
[7] UOC Ematol Trapianto Cellule Staminali, CROB, Naples, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：140 / 140
页数：1
相关论文
共 50 条
  • [31] Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
    Castro, T. B. M.
    Hallack Neto, A. E.
    Atalla, A.
    Ribeiro, L. C.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2016, 49 (06) : e5128
  • [32] Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    San Miguel, Jesus F.
    Schlag, Rudolf
    Khuageva, Nuriet K.
    Dimopoulos, Meletios A.
    Shpilberg, Ofer
    Kropff, Martin
    Spicka, Ivan
    Petrucci, Maria T.
    Palumbo, Antonio
    Samoilova, Olga S.
    Dmoszynska, Anna
    Abdulkadyrov, Kudrat M.
    Schots, Rik
    Jiang, Bin
    Mateos, Maria-Victoria
    Anderson, Kenneth C.
    Esseltine, Dixie L.
    Liu, Kevin
    Cakana, Andrew
    van de Velde, Helgi
    Richardson, Paul G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09): : 906 - 917
  • [33] Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
    Lee, Se Ryeon
    Choi, Hojoon
    Lee, Byung Hyun
    Kang, Ka-Won
    Yu, Eun Sang
    Kim, Dae Sik
    Park, Yong
    Choi, Chul Won
    Kim, Byung Soo
    Sung, Hwa Jung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (06): : 1333 - 1346
  • [34] Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone
    Hou, Jian
    Fu, Weijun
    Bang, Soo-Mee
    Huang, Honghui
    Kim, Kihyun
    Li, Wei
    An, Gang
    Lee, Je-Jung
    Cai, Zhen
    Jin, Jie
    Wang, Yafei
    Chim, C. S.
    Rodriguez-Otero, Paula
    Dimopoulos, Meletios A.
    Fujisaki, Tomoaki
    Lee, Jae Hoon
    Wroblewski, Susan
    Carson, Robin
    Qi, Ming
    Wang, Jianping
    Song, Yang
    Bin Jia
    Yang, Xue
    Liu, Wenyu
    Li, Yunan
    Zhang, Renyi
    Wang, Jianxiang
    BLOOD, 2021, 138
  • [35] Bortezomib- melphalan-prednisone: what pattern for bortezomib in multiple myeloma?
    Fouquet, Guillemette
    Leleu, Xavier
    HEMATOLOGIE, 2015, 21 (03): : 157 - 159
  • [36] Velcade™ plus Melphalan, Prednisone, and Thalidomide (V-MPT) for advanced multiple myeloma.
    Palumbo, A
    Ambrosini, MT
    Pregno, P
    Pescosta, N
    Callea, V
    Cangialosi, C
    Caravita, T
    Morabito, F
    Omedè, P
    Gay, F
    Avonto, I
    Falco, P
    Bringhen, S
    Boccadoro, M
    BLOOD, 2005, 106 (11) : 717A - 717A
  • [37] Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
    Palumbo, A
    Bertola, A
    Musto, P
    Caravita, T
    Callea, V
    Nunzi, M
    Grasso, M
    Falco, P
    Cangialosi, C
    Boccadoro, M
    CANCER, 2005, 104 (07) : 1428 - 1433
  • [38] The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
    Kim, Cheolsu
    Lee, Ho Sup
    Min, Chang-Ki
    Lee, Je Jung
    Kim, Kihyun
    Yoon, Dok Hyun
    Eom, Hyeon Seok
    Lee, Hyewon
    Lee, Won Sik
    Shin, Ho-Jin
    Lee, Ji Hyun
    Park, Yong
    Jo, Jae-Cheol
    Do, Young Rok
    Mun, Yeung-Chul
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2015, 30 (05): : 675 - 683
  • [39] LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Palumbo, A.
    Falco, P.
    Sanpaolo, G.
    Falcone, A.
    Ferderico, V.
    Canepa, L.
    Crugnola, M.
    Baldini, L.
    Caltagirone, S.
    Larocca, A.
    Gay, F.
    Magarotto, V.
    Petrucci, M. T.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 256 - 256
  • [40] Thalidomide increases the activity of melphalan/prednisone in newly diagnosed multiple myeloma
    不详
    CLINICAL LYMPHOMA, 2004, 5 (02): : 76 - 77
12345